This website uses technical, customisation and analytical cookies, both first-party and third-party, to anonymously facilitate browsing and analyse statistics on use of the website. Learn more
Search results
-
The e-Choupal Initiative
Horniman, Alexander B.; Venkataraman, S.; Thiemele, Anne-Laure; Mead, JennyCase DARDEN-E-0343-EBusiness Ethics and Corporate Social ResponsibilityAn international corporation’s agricultural business division reviews its seven-year-old IT initiative among rural Indian farmers. Suitable for learners at all levels, the case is ideal for modules on strategic change, transformational change in a value chain, and development at the bottom of the pyramid. It also provides excellent insight into how corporations can improve both profits and lifestyles in developing nations while bolstering their w...Starting at €8.20
-
E-Cigarettes: The Wild, Wild West
Farris, Paul W.; Wicks, Andrew C.; Mead, Jenny; Abbott, KatherineCase DARDEN-M-0876-EMarketingIn 2014, tobacco giant Reynolds American Inc. (RAI) had to confront the rapidly evolving global tobacco industry landscape. E-cigarettes, once considered a fad, were becoming increasingly popular. Facing uncharted territory, tobacco companies were uncertain about how to most successfully enter this market and how to do so rapidly.Starting at €8.20
-
Looking for (e)Harmony
Wicks, Andrew C.; Mead, Jenny; Shariff, IkramCase DARDEN-BRI-1003-EBusiness Ethics and Corporate Social ResponsibilityA growing company has an opportunity to sign a major client: an online dating service. But that service is notorious for having forbidden ads indicating a search for same-sex partnerships. That policy goes against the corporation's own ethics and the personal views of many of its employees. Yet the company needs a large contract such as this one to sustain itself. What should the company decide to do?Starting at €8.20
-
Comergent Technologies Inc.: Enterprise E-Commerce, Teaching Note
Rangan, V. Kasturi; Bellfor, MarieTeaching Note HBS-507087-EMarketingTeaching Note to (505-016). An abstract is not available for this product.Starting at €0.00
-
Out for Blood: Tyler Shultz and Theranos (E)
Harris, Jared D.; Agle, Bradley R.; Mead, Jenny; Scoville, JimmyCase DARDEN-E-0440H4-EBusiness Ethics and Corporate Social ResponsibilityIn early 2014, recent Stanford University graduate Tyler Shultz was in a quandary. He had been working at Theranos, a blood-diagnostic company founded by Elizabeth Holmes, a Stanford-dropout wunderkind, for almost a year. Shultz had learned enough about tStarting at €5.74
-
E-Cigarettes: The Wild, Wild West - Teaching Note
Farris, Paul W.; Wicks, Andrew C.; Mead, JennyTeaching Note DARDEN-M-0876TN-EMarketingTeaching note for product M-0876Starting at €0.00
-
Rio Tinto and the Resolution Copper Mining Joint Venture (A), (B), and (C) - Teaching Note
Werhane, Patricia H.; Gorman, Michael E.; Mead, Jenny; Starr, JustinTeaching Note DARDEN-E-0373TN-EBusiness Ethics and Corporate Social ResponsibilityTeaching note for product E-0373Starting at €0.00
-
Juul Labs: Guilty by Association?
Wicks, Andrew C.; Wang, Yuhan; Pak, Sally; Botha, Helet; Mead, JennyCase DARDEN-E-0471-EBusiness Ethics and Corporate Social ResponsibilityThe protagonist, the CEO of Juul Labs (Juul), an e-cigarette company founded to help smokers quit cigarettes, is trying to negotiate a merger with Philip Morris International (PMI), the behemoth tobacco company, in the face of bad press about e-cigarettesStarting at €8.20
-
Gilead: Hepatitis-C Access Strategy (A)
Rangan, V. Kasturi; Rangan, Vikram; Bloom, David E.Case HBS-515025-EGilead had come up with an innovative drug for Hepatitis C, which affected 180 million people worldwide. The drug was priced at $1,000 a pill for the US market. Gilead had to decide how to price and market the pill in developing countries that bore the brunt of the disease. The company had earned accolades for its work in HIV/AIDS, where its innovative medicines now accounted for 60% of all patients on Anti-Retroviral (ARV) medicines. Much of thi...Starting at €8.20
-
Sanofi Pasteur: The Dengue Vaccine Dilemma
Rangan, V. Kasturi; Bloom, David E.; Dessain, Vincent; Billaud, EmilieCase HBS-514074-EIn 2012, Sanofi Pasteur was racing to develop a vaccine against dengue, a mosquito-borne disease, and was evaluating this product in a Phase IIb trial conducted with school children in Thailand. But while the candidate vaccine met the high safety expectations and a good balanced immune answer, it had a proof of efficacy of only 30%, far below the 70% mark the company had targeted. Guillaume Leroy, vice president of the Dengue Company at Sanofi Pa...Starting at €8.20